Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.57 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TACR3 | P29371 | 6/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12017074 | 1.00 | CTSB (0.57) | CTSBADRB3ADRA2BADRA2CKDM4E | |
| SCHEMBL3040551 | 1.00 | CTSB (0.57) | CTSBADRB3ADRA2BADRA2CKDM4E | |
| SCHEMBL3048828 | 0.93 | CTSB (0.54) | CTSBADRB3ADRA2BADRA2CKDM4E | |
| SCHEMBL3048824 | 0.93 | CTSB (0.54) | CTSBADRB3ADRA2BADRA2CKDM4E | |
| SCHEMBL8222778 | 0.93 | CTSB (0.54) | CTSBADRB3ADRA2BADRA2CKDM4E | |
| SCHEMBL13519888 | 0.90 | CTSB (0.60) | CTSBADRB3ADRA2BADRA2CKDM4E | |
| SCHEMBL13335509 | 0.90 | CTSB (0.56) | CTSBADRB3ADRA2BADRA2CKDM4E | |
| SCHEMBL2422425 | 0.90 | CTSB (0.56) | CTSBADRB3ADRA2BADRA2CKDM4E | |
| SCHEMBL2422431 | 0.90 | CTSB (0.56) | CTSBADRB3ADRA2BADRA2CKDM4E | |
| SCHEMBL2422428 | 0.90 | CTSB (0.56) | CTSBADRB3ADRA2BADRA2CKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100003216-A1 | HCV NS-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2010-01-07 | — | — | US | claimed |
| EP-1713822-B1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-03-17 | — | — | EP | disclosed |
| US-20100003216-A1 | HCV NS-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2010-01-07 | — | — | US | disclosed |
| US-7608590-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2009-10-27 | — | — | US | disclosed |
| US-20070161574-A1 | Hcv ns-3 serine protease inhibitors | MEDIVIR AB (SE) | 2007-07-12 | — | — | US | disclosed |
| EP-1713822-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005073216-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003216-A1 | HCV NS-3 Serine Protease Inhibitors | SPINT2, SF3A3, GTF3C3 | CTSB 731/4885ADRB3 2740/4885ADRA2B 4712/4885 |
| US-20070161574-A1 | Hcv ns-3 serine protease inhibitors | PRSS1, HPN, SPINT2 | CTSB 280/4885ADRB3 3967/4885ADRA2B 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.